Company intelligence / Profile preview

Centenara Labs

Schlieren, Zurich, Switzerland

Ownership: Private
Development stage: Other

Overview

EA-2353 (Retinitis Pigmentosa) has completed Phase 1/2a demonstrating safety and signs of efficacy; dry-AMD program has IND clearance, clinical entry planned for 2025. Antibody and telomere programs show promising preclinical and IND-enabling data. Five first-in-class targets identified in early discovery for fibrosis, senescence, oncology, and aging

Therapeutic areas: NephrologyOphthalmologyPulmonologyNeurologyMetabolic DisordersOncology
Modalities: Small moleculeAntibodyCombination therapyDrug combinationPlatform company across multiple modalities
Industry: Biotech

Drug pipeline

3 assets

RST-002

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Strategic pharma partnerships sought; specific names not publicly disclosed

Beyond the preview

Go deeper on Centenara Labs.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Centenara Labs.

Explore the full profile